CDK4/6 Inhibitors in Melanoma: A Comprehensive Review

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Metastatic melanoma historically had a poor prognosis.
• Recent advances include BRAF/MEK inhibitors and anti-PD1 antibodies, revolutionizing treatment.
• However, not all patients benefit from current therapies, necessitating novel approaches.

Purpose of the Study:

• To review the current literature on Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in melanoma treatment.
• To present the molecular and genetic rationale for using CDK4/6 inhibitors in melanoma.
• To summarize preclinical and clinical data, and ongoing trials for CDK4/6 inhibitors in melanoma.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies.
• Analysis of molecular and genetic data relevant to CDK4/6 inhibition in melanoma.
• Summary of ongoing clinical trials investigating CDK4/6 inhibitors.

Main Results:

• Preliminary evidence suggests promising activity of CDK4/6 inhibitors in melanoma.
• CDK4/6 inhibitors are already approved for other cancers, indicating a potential therapeutic window.
• Ongoing clinical trials are evaluating their efficacy and safety in various melanoma settings.

Conclusions:

• CDK4/6 inhibitors represent a promising new therapeutic strategy for melanoma.
• Further clinical investigation is warranted to establish their role in melanoma management.
• These agents may offer benefit to patients who do not respond to or progress on existing treatments.